178 related articles for article (PubMed ID: 8888065)
1. Metalloproteinase inhibitors and the prevention of connective tissue breakdown.
Cawston TE
Pharmacol Ther; 1996; 70(3):163-82. PubMed ID: 8888065
[TBL] [Abstract][Full Text] [Related]
2. Proteinases and inhibitors.
Cawston TE
Br Med Bull; 1995 Apr; 51(2):385-401. PubMed ID: 7552071
[TBL] [Abstract][Full Text] [Related]
3. Collagenase: a key enzyme in collagen turnover.
Shingleton WD; Hodges DJ; Brick P; Cawston TE
Biochem Cell Biol; 1996; 74(6):759-75. PubMed ID: 9164646
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinases and TIMPs: properties and implications for the rheumatic diseases.
Cawston T
Mol Med Today; 1998 Mar; 4(3):130-7. PubMed ID: 9575496
[TBL] [Abstract][Full Text] [Related]
5. Proteinases involved in matrix turnover during cartilage and bone breakdown.
Cawston TE; Young DA
Cell Tissue Res; 2010 Jan; 339(1):221-35. PubMed ID: 19915869
[TBL] [Abstract][Full Text] [Related]
6. Stromelysin 1, neutrophil collagenase, and collagenase 3 do not play major roles in a model of chondrocyte mediated cartilage breakdown.
Kozaci LD; Brown CJ; Adcocks C; Galloway A; Hollander AP; Buttle DJ
Mol Pathol; 1998 Oct; 51(5):282-6. PubMed ID: 10193524
[TBL] [Abstract][Full Text] [Related]
7. In vivo model of cartilage degradation--effects of a matrix metalloproteinase inhibitor.
Karran EH; Young TJ; Markwell RE; Harper GP
Ann Rheum Dis; 1995 Aug; 54(8):662-9. PubMed ID: 7677443
[TBL] [Abstract][Full Text] [Related]
8. Role and regulation of metalloproteinases in connective tissue turnover.
Murphy G; Hembry RM; Hughes CE; Fosang AJ; Hardingham TE
Biochem Soc Trans; 1990 Oct; 18(5):812-5. PubMed ID: 2083684
[No Abstract] [Full Text] [Related]
9. Activation of procollagenases is a key control point in cartilage collagen degradation: interaction of serine and metalloproteinase pathways.
Milner JM; Elliott SF; Cawston TE
Arthritis Rheum; 2001 Sep; 44(9):2084-96. PubMed ID: 11592371
[TBL] [Abstract][Full Text] [Related]
10. The functional balance of metalloproteinases and inhibitors in tissue degradation: relevance to oral pathologies.
Reynolds JJ; Meikle MC
J R Coll Surg Edinb; 1997 Jun; 42(3):154-60. PubMed ID: 9195805
[TBL] [Abstract][Full Text] [Related]
11. Metalloproteinase inhibitors as therapeutics.
Gordon JL; Drummond AH; Galloway WA
Clin Exp Rheumatol; 1993; 11 Suppl 8():S91-4. PubMed ID: 8391953
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-1 and oncostatin M in combination promote the release of collagen fragments from bovine nasal cartilage in culture.
Cawston TE; Ellis AJ; Humm G; Lean E; Ward D; Curry V
Biochem Biophys Res Commun; 1995 Oct; 215(1):377-85. PubMed ID: 7575616
[TBL] [Abstract][Full Text] [Related]
13. Leukemic cells (HL-60) produce a novel extracellular matrix-degrading proteinase that is not inhibited by tissue inhibitors of matrix metalloproteinases (TIMPs).
Dittmann KH; Lottspeich F; Ries C; Petrides PE
Exp Hematol; 1995 Feb; 23(2):155-60. PubMed ID: 7828672
[TBL] [Abstract][Full Text] [Related]
14. Adenoviral gene transfer of interleukin-1 in combination with oncostatin M induces significant joint damage in a murine model.
Rowan AD; Hui W; Cawston TE; Richards CD
Am J Pathol; 2003 Jun; 162(6):1975-84. PubMed ID: 12759253
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the degradation of type II collagen and proteoglycan in nasal and articular cartilages induced by interleukin-1 and the selective inhibition of type II collagen cleavage by collagenase.
Billinghurst RC; Wu W; Ionescu M; Reiner A; Dahlberg L; Chen J; van Wart H; Poole AR
Arthritis Rheum; 2000 Mar; 43(3):664-72. PubMed ID: 10728761
[TBL] [Abstract][Full Text] [Related]
16. Degradation of type II collagen, but not proteoglycan, correlates with matrix metalloproteinase activity in cartilage explant cultures.
Kozaci LD; Buttle DJ; Hollander AP
Arthritis Rheum; 1997 Jan; 40(1):164-74. PubMed ID: 9008612
[TBL] [Abstract][Full Text] [Related]
17. A synthetic peptide metalloproteinase inhibitor, but not TIMP, prevents the breakdown of proteoglycan within articular cartilage in vitro.
Andrews HJ; Plumpton TA; Harper GP; Cawston TE
Agents Actions; 1992 Sep; 37(1-2):147-54. PubMed ID: 1456176
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP).
Murphy G; Cockett MI; Ward RV; Docherty AJ
Biochem J; 1991 Jul; 277 ( Pt 1)(Pt 1):277-9. PubMed ID: 1649600
[TBL] [Abstract][Full Text] [Related]
19. Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1).
Dahlberg L; Billinghurst RC; Manner P; Nelson F; Webb G; Ionescu M; Reiner A; Tanzer M; Zukor D; Chen J; van Wart HE; Poole AR
Arthritis Rheum; 2000 Mar; 43(3):673-82. PubMed ID: 10728762
[TBL] [Abstract][Full Text] [Related]
20. The regulation of MMPs and TIMPs in cartilage turnover.
Cawston T; Billington C; Cleaver C; Elliott S; Hui W; Koshy P; Shingleton B; Rowan A
Ann N Y Acad Sci; 1999 Jun; 878():120-9. PubMed ID: 10415724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
